RedShift BioAnalytics, Inc. (RedShiftBio), a provider of analytical instrumentation for the characterization of protein therapeutics, is pleased to announce the completion of Phase II of the company’s collaborative trials. Conducted alongside leading academic and industrial biologic institutions, the collaborative testing has demonstrated the clear advantages of the company’s patented Microfluidic Modulation Spectroscopy (MMS) platform. Simultaneously, the company launched its new website to provide important new information on the technology and its bioanalytical capabilities.
Following the closing of last year’s $11 Million Series C equity financing, RedShiftBio accelerated commercialization of the MMS platform in preparation for an upcoming 2018 product launch. Participants in last year’s equity financing included Waters Corporation (NYSE: WAT), the world's leading specialty measurement company in the development and manufacture of innovative analytical solutions, and Technology Venture Partners, a venture capital firm specializing in technology and healthcare.
‘We’re very impressed with initial results produced by the RedShiftBio platform,’ ...
